KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
The KDIGO 2024 Clinical Practice Guideline provides updated, GRADE-based recommendations for evaluating and managing chronic kidney disease in adults and children not receiving kidney replacement therapy.
Background
This KDIGO guideline updates the 2012 CKD guidance and was developed with patient partners, clinicians, and researchers globally. It is intended for people with CKD who are not receiving dialysis or a kidney transplant, and reflects a substantially broader evidence base than was previously available.
Key recommendations
Per the published synopsis, the full guideline includes 28 recommendations and 141 practice points. Key recommendations include greater emphasis on cystatin C for GFR assessment, a shift to an individualised risk-based approach to predict kidney failure, sodium-glucose cotransporter-2 inhibitors for selected patients with CKD with and without diabetes, and statin use for adults older than 50 years with CKD.
Clinical implications
Treatment approaches are based on systematic reviews appraised with the GRADE approach, supplemented by practice points reflecting expert opinion where evidence is weaker. The guideline addresses evaluation and risk assessment, delaying progression and complications, medication management and drug stewardship, and models of CKD care, while remaining sensitive to international and lifespan considerations.
Category
KDIGO
Source
Kidney Int
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.